NR565 ADVANCED PHARMACOLOGY CARE OF THE
FUNDAMENTALS MIDTERM EXAM 2026/2027 | Questions and
Verified Answers | Chamberlain | Pass Guaranteed - A+
Graded
Unit 1: Pharmacokinetics & Pharmacodynamics (15 Questions)
Q1: A 68-year-old male with a history of chronic kidney disease (eGFR 35
mL/min/1.73m²) is prescribed gentamicin 80mg IV q8h for a complicated urinary tract
infection. The drug has a half-life of 2 hours in patients with normal renal function.
Which pharmacokinetic principle should guide the nurse practitioner's dosing decision?
A. Increase the dose frequency to q6h to maintain therapeutic levels in renal impairment
B. Extend the dosing interval to q24-48h due to reduced renal clearance and prolonged
half-life [CORRECT]
C. Administer the standard dose with increased fluid intake to enhance renal elimination
D. Switch to oral gentamicin to reduce systemic exposure
Correct Answer: B
Rationale: In renal impairment, drugs primarily eliminated by the kidneys (like
aminoglycosides) experience prolonged half-life and reduced clearance. Gentamicin is
nephrotoxic and requires dose adjustment in CKD. The correct approach is extending
the dosing interval while maintaining the same dose (or reducing dose while keeping
interval) to prevent accumulation and toxicity. Option A is incorrect because more
,frequent dosing would cause drug accumulation and nephrotoxicity/ototoxicity. Option
C is incorrect because increased fluids do not compensate for reduced glomerular
filtration. Option D is incorrect because aminoglycosides have poor oral bioavailability
(<1%) and cannot be used orally for systemic infections.
Q2: A nurse practitioner is teaching a patient about warfarin therapy. The patient asks
why it takes several days to achieve therapeutic anticoagulation despite starting therapy
immediately. The NP should explain this phenomenon based on which
pharmacodynamic principle?
A. Warfarin is a prodrug requiring hepatic activation
B. The drug inhibits synthesis of new clotting factors while existing factors must be
consumed [CORRECT]
C. Warfarin undergoes extensive first-pass metabolism
D. The therapeutic index requires gradual dose titration
Correct Answer: B
Rationale: Warfarin inhibits vitamin K epoxide reductase, preventing synthesis of vitamin
K-dependent clotting factors (II, VII, IX, X). However, existing circulating clotting factors
must be naturally cleared (factor VII has the shortest half-life at 6 hours, factor II at 60
hours). This explains the delayed onset of action (36-72 hours). Option A is
incorrect—warfarin is not a prodrug. Option C is incorrect—while warfarin does undergo
hepatic metabolism, first-pass effects don't explain the delayed therapeutic effect.
Option D is incorrect—although warfarin has a narrow therapeutic index, this doesn't
explain the pharmacodynamic delay in achieving anticoagulation.
,Q3: A 45-year-old female with epilepsy is prescribed phenytoin. After 2 weeks of therapy
at 300mg/day, her serum level is 8 mcg/mL (therapeutic range 10-20 mcg/mL). The NP
increases the dose to 400mg/day. At 3 weeks, her level is 18 mcg/mL. Which
pharmacokinetic principle explains this disproportionate increase?
A. Zero-order kinetics at higher concentrations [CORRECT]
B. Increased bioavailability with chronic dosing
C. Auto-induction of metabolism
D. Increased protein binding at higher doses
Correct Answer: A
Rationale: Phenytoin exhibits capacity-limited (zero-order) metabolism at therapeutic
concentrations. Below 10 mcg/mL, metabolism follows first-order kinetics; above this
threshold, hepatic enzymes become saturated, and metabolism proceeds at a constant
rate regardless of concentration. Small dose increases can produce disproportionately
large serum level increases. Option B is incorrect—bioavailability doesn't change with
chronic dosing. Option C is incorrect—while some drugs auto-induce metabolism,
phenytoin does not; carbamazepine does. Option D is incorrect—phenytoin is highly
protein bound (90%), but binding doesn't increase with dose; saturation of metabolism,
not protein binding, explains this pattern.
Q4: A patient receiving digoxin 0.25mg daily develops toxicity (nausea, vomiting, visual
disturbances) with a serum level of 3.2 ng/mL (therapeutic 0.5-0.9 ng/mL). The NP
, notes the patient recently started amiodarone for atrial fibrillation. Which fundamental
pharmacokinetic interaction explains this toxicity?
A. Amiodarone induces P-glycoprotein, increasing digoxin renal clearance
B. Amiodarone inhibits P-glycoprotein and competes for renal tubular secretion,
reducing digoxin clearance by 70% [CORRECT]
C. Amiodarone displaces digoxin from protein binding sites
D. Amiodarone increases digoxin absorption from the GI tract
Correct Answer: B
Rationale: Digoxin is a P-glycoprotein substrate. Amiodarone inhibits P-glycoprotein in
the gut (reducing efflux back into intestinal lumen) and kidneys (reducing tubular
secretion), and potentially inhibits hepatic metabolism. This reduces digoxin clearance
by approximately 70%, requiring a 50% dose reduction when initiating amiodarone.
Option A is incorrect—amiodarone inhibits, not induces, P-glycoprotein. Option C is
incorrect—digoxin is not highly protein bound (20-30%), so displacement is clinically
insignificant. Option D is incorrect—while amiodarone does increase bioavailability
slightly, the primary mechanism is reduced renal clearance via P-glycoprotein inhibition.
Q5: A nurse practitioner is explaining steady-state concentration to a nursing student.
Which statement accurately describes when steady-state is achieved for a drug with a
half-life of 6 hours?
A. After approximately 6 hours of continuous infusion
B. After approximately 30 hours (5 half-lives) of regular dosing [CORRECT]
FUNDAMENTALS MIDTERM EXAM 2026/2027 | Questions and
Verified Answers | Chamberlain | Pass Guaranteed - A+
Graded
Unit 1: Pharmacokinetics & Pharmacodynamics (15 Questions)
Q1: A 68-year-old male with a history of chronic kidney disease (eGFR 35
mL/min/1.73m²) is prescribed gentamicin 80mg IV q8h for a complicated urinary tract
infection. The drug has a half-life of 2 hours in patients with normal renal function.
Which pharmacokinetic principle should guide the nurse practitioner's dosing decision?
A. Increase the dose frequency to q6h to maintain therapeutic levels in renal impairment
B. Extend the dosing interval to q24-48h due to reduced renal clearance and prolonged
half-life [CORRECT]
C. Administer the standard dose with increased fluid intake to enhance renal elimination
D. Switch to oral gentamicin to reduce systemic exposure
Correct Answer: B
Rationale: In renal impairment, drugs primarily eliminated by the kidneys (like
aminoglycosides) experience prolonged half-life and reduced clearance. Gentamicin is
nephrotoxic and requires dose adjustment in CKD. The correct approach is extending
the dosing interval while maintaining the same dose (or reducing dose while keeping
interval) to prevent accumulation and toxicity. Option A is incorrect because more
,frequent dosing would cause drug accumulation and nephrotoxicity/ototoxicity. Option
C is incorrect because increased fluids do not compensate for reduced glomerular
filtration. Option D is incorrect because aminoglycosides have poor oral bioavailability
(<1%) and cannot be used orally for systemic infections.
Q2: A nurse practitioner is teaching a patient about warfarin therapy. The patient asks
why it takes several days to achieve therapeutic anticoagulation despite starting therapy
immediately. The NP should explain this phenomenon based on which
pharmacodynamic principle?
A. Warfarin is a prodrug requiring hepatic activation
B. The drug inhibits synthesis of new clotting factors while existing factors must be
consumed [CORRECT]
C. Warfarin undergoes extensive first-pass metabolism
D. The therapeutic index requires gradual dose titration
Correct Answer: B
Rationale: Warfarin inhibits vitamin K epoxide reductase, preventing synthesis of vitamin
K-dependent clotting factors (II, VII, IX, X). However, existing circulating clotting factors
must be naturally cleared (factor VII has the shortest half-life at 6 hours, factor II at 60
hours). This explains the delayed onset of action (36-72 hours). Option A is
incorrect—warfarin is not a prodrug. Option C is incorrect—while warfarin does undergo
hepatic metabolism, first-pass effects don't explain the delayed therapeutic effect.
Option D is incorrect—although warfarin has a narrow therapeutic index, this doesn't
explain the pharmacodynamic delay in achieving anticoagulation.
,Q3: A 45-year-old female with epilepsy is prescribed phenytoin. After 2 weeks of therapy
at 300mg/day, her serum level is 8 mcg/mL (therapeutic range 10-20 mcg/mL). The NP
increases the dose to 400mg/day. At 3 weeks, her level is 18 mcg/mL. Which
pharmacokinetic principle explains this disproportionate increase?
A. Zero-order kinetics at higher concentrations [CORRECT]
B. Increased bioavailability with chronic dosing
C. Auto-induction of metabolism
D. Increased protein binding at higher doses
Correct Answer: A
Rationale: Phenytoin exhibits capacity-limited (zero-order) metabolism at therapeutic
concentrations. Below 10 mcg/mL, metabolism follows first-order kinetics; above this
threshold, hepatic enzymes become saturated, and metabolism proceeds at a constant
rate regardless of concentration. Small dose increases can produce disproportionately
large serum level increases. Option B is incorrect—bioavailability doesn't change with
chronic dosing. Option C is incorrect—while some drugs auto-induce metabolism,
phenytoin does not; carbamazepine does. Option D is incorrect—phenytoin is highly
protein bound (90%), but binding doesn't increase with dose; saturation of metabolism,
not protein binding, explains this pattern.
Q4: A patient receiving digoxin 0.25mg daily develops toxicity (nausea, vomiting, visual
disturbances) with a serum level of 3.2 ng/mL (therapeutic 0.5-0.9 ng/mL). The NP
, notes the patient recently started amiodarone for atrial fibrillation. Which fundamental
pharmacokinetic interaction explains this toxicity?
A. Amiodarone induces P-glycoprotein, increasing digoxin renal clearance
B. Amiodarone inhibits P-glycoprotein and competes for renal tubular secretion,
reducing digoxin clearance by 70% [CORRECT]
C. Amiodarone displaces digoxin from protein binding sites
D. Amiodarone increases digoxin absorption from the GI tract
Correct Answer: B
Rationale: Digoxin is a P-glycoprotein substrate. Amiodarone inhibits P-glycoprotein in
the gut (reducing efflux back into intestinal lumen) and kidneys (reducing tubular
secretion), and potentially inhibits hepatic metabolism. This reduces digoxin clearance
by approximately 70%, requiring a 50% dose reduction when initiating amiodarone.
Option A is incorrect—amiodarone inhibits, not induces, P-glycoprotein. Option C is
incorrect—digoxin is not highly protein bound (20-30%), so displacement is clinically
insignificant. Option D is incorrect—while amiodarone does increase bioavailability
slightly, the primary mechanism is reduced renal clearance via P-glycoprotein inhibition.
Q5: A nurse practitioner is explaining steady-state concentration to a nursing student.
Which statement accurately describes when steady-state is achieved for a drug with a
half-life of 6 hours?
A. After approximately 6 hours of continuous infusion
B. After approximately 30 hours (5 half-lives) of regular dosing [CORRECT]
